Myelodysplastic Syndromes (MDS)
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
Purpose: In myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes
Approximately 90% of patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez)
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
Disease overview: The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN
Therapy-related myelodysplastic syndromes in the genomics era
Therapy-related myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorder
Raising the bar for lower-risk myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone